Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation

Fig. 5

Biosafety and biodistribution of Pt@PCN-Cu. (A) Body weight changes in healthy C57BL/6 mice treated with PBS, ES, CuCl2 + ES and Pt@PCN-Cu, respectively. (B-H) Serum biochemical analysis of mice after various treatments: (B) ALT, (C) AST, (D) CK (E) Crea, (F) DBIL, (G) TBIL and (H) urea. (I) Histological assessment of major organs (heart, liver, spleen, lungs and kidneys) by H&E staining after various treatments. Scale bar: 50 μm. (J) In vivo biodistribution of Pt@PCN-Cu@Cy7.5. (K) Ex vivo imaging of tumors and major organs 24 h after administration of Pt@PCN-Cu@Cy7.5. Data are presented as mean ± SD

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us